Opendata, web and dolomites

MycoSynVac SIGNED

Engineering of Mycoplasma pneumoniae as a broad-spectrum animal vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MycoSynVac project word cloud

Explore the words cloud of the MycoSynVac project. It provides you a very rough idea of what is the project "MycoSynVac" about.

860    cow    public    vaccinate    risks    wall    aside    ethical    pigs    grow    species    cell    euros    vaccine    contamination    gallisepticum    axenic    small    metabolic    medium    engineering    infecting    material    livestock    modeling    resistant    meet    usa    position    data    point    world    privileged    create    display    antibiotics    media    chassis    viruses    prepare    cheap    ultimate    mycoplasmas    specialized    farm    ie    humans    industrial    free    pathogen    caused    mycoplasma    screening    poultry    smallest    care    reproducible    pneumoniae    peptide    starting    organism    acquired    hyopneumoniae    genome    guided    living    ideal    vaccines    lack    microorganisms    kb    serum    biology    pipeline    vaccination    infection    grown    industry    multimillion    training    highlights    designing    commercialization    infections    pets    bovis    rationally    cows    losses    msd    animals    difficult    probably    foreseeable    sme    culture    synoviae    universal    animal    irreproducibility   

Project "MycoSynVac" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO CENTRE DE REGULACIO GENOMICA 

Organization address
address: CARRER DOCTOR AIGUADER 88
city: BARCELONA
postcode: 8003
website: www.crg.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.mycosynvac.eu
 Total cost 8˙056˙677 €
 EC max contribution 8˙056˙677 € (100%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
 Code Call H2020-LEIT-BIO-2014-1
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) coordinator 2˙128˙507.00
2    INTERVET INTERNATIONAL BV NL (BOXMEER) participant 1˙476˙250.00
3    ATG:BIOSYNTHETICS GMBH DE (MERZHAUSEN) participant 897˙493.00
4    WAGENINGEN UNIVERSITY NL (WAGENINGEN) participant 860˙008.00
5    INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT FR (PARIS CEDEX 07) participant 850˙300.00
6    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 699˙977.00
7    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 591˙750.00
8    BIOFACTION KG AT (WIEN) participant 552˙392.00

Map

 Project objective

Mycoplasmas are the smallest cell wall less, free-living microorganisms. The lack of a cell wall makes them resistant to many of the common antibiotics. Every year, infections caused by Mycoplasmas in poultry, cows, and pigs, result in multimillion euros losses in USA and Europe. Currently, there are vaccines against M hyopneumoniae in pigs and M gallisepticum and M synoviae in poultry. However, there is no vaccination against many Mycoplasma species infecting pets, humans and farm animals (ie M bovis cow infection). Mycoplasma species in many cases are difficult to grown in axenic culture and those that grow need a complex media with animal serum. In large scale production of Mycoplasma species for vaccination aside from the high cost of animal serum, more important is the high irreproducibility in the production process and the possible contamination with animal viruses. All this together highlights what European industry needs:i) a defined cheap reproducible medium that is animal serum free and ii) an universal Mycoplasma chassis that could be used in a pipeline to vaccinate against Mycoplasma species, as well as any pathogen. M pneumoniae is an ideal starting point for designing such a vaccine chassis. It has a small genome (860 kb) and it is probably the organism with the most comprehensive systems biology data acquired so far. By genome comparison, metabolic modeling and rationally engineering its genome, we will create a vaccine chassis that will be introduced into an industrial pipeline. The process will be guided by the second world largest industry on animal vaccination (MSD), as well as a SME specialized on peptide display and screening. This will ensure the exploitation and commercialization of our work contributing to maintain Europe privileged position in this field. Our ultimate goal is to meet the needs of the livestock industry,taking care of ethical issues, foreseeable risks, and prepare effective dissemination and training material for the public.

 Deliverables

List of deliverables.
Science game Websites, patent fillings, videos etc. 2020-04-22 09:58:36
Public and expert concerns Documents, reports 2020-04-22 09:58:36
Ethical framework Documents, reports 2020-04-22 09:58:36
Empirical and ethical studies Documents, reports 2020-04-22 09:58:35
Lorentz Workshop on Whole Cell modeling Documents, reports 2020-04-22 09:58:35
Project website Websites, patent fillings, videos etc. 2020-04-22 09:58:35

Take a look to the deliverables list in detail:  detailed list of MycoSynVac deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Eva Yus, Jae-Seong Yang, Adrià Sogues, Luis Serrano
A reporter system coupled with high-throughput sequencing unveils key bacterial transcription and translation determinants
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-017-00239-7
Nature Communications 8/1 2020-04-22
2017 Marie Trussart, Eva Yus, Sira Martinez, Davide Baù, Yuhei O. Tahara, Thomas Pengo, Michael Widjaja, Simon Kretschmer, Jim Swoger, Steven Djordjevic, Lynne Turnbull, Cynthia Whitchurch, Makoto Miyata, Marc A. Marti-Renom, Maria Lluch-Senar, Luís Serrano
Defined chromosome structure in the genome-reduced bacterium Mycoplasma pneumoniae
published pages: 14665, ISSN: 2041-1723, DOI: 10.1038/ncomms14665
Nature Communications 8 2020-04-22
2018 Robert W. Smith, Rik P. van Rosmalen, Vitor A. P. Martins dos Santos, Christian Fleck
DMPy: a Python package for automated mathematical model construction of large-scale metabolic systems
published pages: , ISSN: 1752-0509, DOI: 10.1186/s12918-018-0584-8
BMC Systems Biology 12/1 2020-04-22
2018 Niels Zondervan, Jesse van Dam, Peter Schaap, Vitor Martins dos Santos, Maria Suarez-Diez
Regulation of Three Virulence Strategies of Mycobacterium tuberculosis: A Success Story
published pages: 347, ISSN: 1422-0067, DOI: 10.3390/ijms19020347
International Journal of Molecular Sciences 19/2 2020-04-22
2017 Tjerko Kamminga, Simen-Jan Slagman, Jetta J. E. Bijlsma, Vitor A. P. Martins dos Santos, Maria Suarez-Diez, Peter J. Schaap
Metabolic modeling of energy balances in Mycoplasma hyopneumoniae shows that pyruvate addition increases growth rate
published pages: , ISSN: 0006-3592, DOI: 10.1002/bit.26347
Biotechnology and Bioengineering 2020-04-22
2015 Maria Lluch-Senar, Luca Cozzuto, Jaime Cano, Javier Delgado, Verónica Llórens-Rico, Sabine Pereyre, Cécile Bebear, Luis Serrano
Comparative “-omics” in Mycoplasma pneumoniae Clinical Isolates Reveals Key Virulence Factors
published pages: e0137354, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0137354
PLOS ONE 10/9 2020-04-22
2016 Iason Tsarmpopoulos, Géraldine Gourgues, Alain Blanchard, Sanjay Vashee, Joerg Jores, Carole Lartigue, Pascal Sirand-Pugnet
In-Yeast Engineering of a Bacterial Genome Using CRISPR/Cas9
published pages: 104-109, ISSN: 2161-5063, DOI: 10.1021/acssynbio.5b00196
ACS Synthetic Biology 5/1 2020-04-22
2016 Ivan Junier, E. Besray Unal, Eva Yus, Verónica Lloréns-Rico, Luis Serrano
Insights into the Mechanisms of Basal Coordination of Transcription Using a Genome-Reduced Bacterium
published pages: 391-401, ISSN: 2405-4712, DOI: 10.1016/j.cels.2016.04.015
Cell Systems 2/6 2020-04-22
2017 Tjerko Kamminga, Jasper J. Koehorst, Paul Vermeij, Simen-Jan Slagman, Vitor A. P. Martins dos Santos, Jetta J. E. Bijlsma, Peter J. Schaap
Persistence of Functional Protein Domains in Mycoplasma Species and their Role in Host Specificity and Synthetic Minimal Life
published pages: , ISSN: 2235-2988, DOI: 10.3389/fcimb.2017.00031
Frontiers in Cellular and Infection Microbiology 7 2020-04-22
2016 Maria Lluch-Senar, Francesco M. Mancuso, Héctor Climente-González, Marcia I. Peña-Paz, Eduard Sabido, Luis Serrano
Rescuing discarded spectra: Full comprehensive analysis of a minimal proteome
published pages: 554-563, ISSN: 1615-9853, DOI: 10.1002/pmic.201500187
PROTEOMICS 16/4 2020-04-22
2016 Wei-Hua Chen, Vera van Noort, Maria Lluch-Senar, Marco L. Hennrich, Judith A. H. Wodke, Eva Yus, Andreu Alibés, Guglielmo Roma, Daniel R. Mende, Christina Pesavento, Athanasios Typas, Anne-Claude Gavin, Luis Serrano, Peer Bork
Integration of multi-omics data of a genome-reduced bacterium: Prevalence of post-transcriptional regulation and its correlation with protein abundances
published pages: 1192-1202, ISSN: 0305-1048, DOI: 10.1093/nar/gkw004
Nucleic Acids Research 44/3 2020-04-22
2018 Rienk A. Rienksma, Peter J. Schaap, Vitor A. P. Martins dos Santos, Maria Suarez-Diez
Modeling the Metabolic State of Mycobacterium tuberculosis Upon Infection
published pages: , ISSN: 2235-2988, DOI: 10.3389/fcimb.2018.00264
Frontiers in Cellular and Infection Microbiology 8 2020-04-22
2018 Lei Pei, Markus Schmidt
Fast-Growing Engineered Microbes: New Concerns for Gain-of-Function Research?
published pages: , ISSN: 1664-8021, DOI: 10.3389/fgene.2018.00207
Frontiers in Genetics 9 2020-04-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYCOSYNVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYCOSYNVAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.)

SHIKIFACTORY100 (2019)

Modular cell factories for the production of 100 compounds from the shikimate pathway

Read More  

BioRoboost (2018)

Fostering Synthetic Biology standardisation through international collaboration

Read More  

SynBio4Flav (2019)

Synthetic microbial consortia-based platform for flavonoids production using synthetic biology

Read More